Photo from archive.org
The phase III IMmotion151 trial found that the combination of atezolizumab and bevacizumab boosts progression-free survival compared with sunitinib in patients with advanced or metastatic renal cell carcinoma. The increase… Click to show full abstract
The phase III IMmotion151 trial found that the combination of atezolizumab and bevacizumab boosts progression-free survival compared with sunitinib in patients with advanced or metastatic renal cell carcinoma. The increase was 2.8 months in all patients and 3.5 months in patients with PD-L1-positive tumors.
Keywords:
drug combo;
sunitinib rcc;
bests sunitinib;
combo bests
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!